Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2003

View Archived Issues

Abgenix and Chugai enter antibody therapeutics agreement

Daiichi selects compound from Pharmacopeia collaboration for preclinical development

GlycoDesign regains rights to Core 2 inhibitors

Sidmak Laboratories to change name to Pliva

New data on the anticancer efficacy of the nitrosourea derivative aranoza

Pfizer claims new 5-HT2C receptor modulators and their use in sexual disorders

Boehringer Ingelheim presents novel thrombin inhibitors

Ferring researchers identify new oxytocin agonists

New series of 5-HT6/5-HT7 ligands discovered at Sigma-Tau

Antibacterial agents discovered in joint research by Essential Therapeutics and Pliva

Novel antiherpesvirus agents in early development at GSK

Schering presents new VEGF inhibitors

New PDE5 inhibitors identified by Lilly Icos team

Research term extended in 3DP thrombin collaboration

IND cleared for NCX-1000

Japanese marketing approval sought for Glivec for GIST indication

AES-14 granted fast track status for oral mucositis associated with cancer chemotherapy

Japanese marketing application for E-7155 withdrawn

Baxter proposes Advate as brand name for rAHF-PFM

Revimid granted fast track designation for relapsed or refractory multiple myeloma

Phase III study initiated for HL-10 in ALI/ARDS

Myriad Genetics discovers DEP1 gene for depression

Cell Genesys refocuses resource investment

MS-325 phase III program completes enrollment

Nuvelo begins trading this week

Novel cytotoxic metabolite isolated from marine bacterium

MIT details the rational design of LMWHs with improved properties

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...